Autres langues Cantargia AB

Actions

CANTA

SE0006371126

Temps Différé Nasdaq Stockholm Autres places de cotation 12:59:40 30/04/2024			Varia. 5j.	Varia. 1 janv.
3,336 ^SEK	-2,74%		-10,56%	-10,75%

17/04	Cantargia publie de nouvelles données sur l'anticorps Can10, détaillant son interaction avec IL1RAP et son inhibition fonctionnelle	CI
10/04	Cantargia AB (publ) publie des données précliniques sur le potentiel du CAN10 dans la sclérose systémique dans un journal scientifique de premier plan	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Cantargia publishes Annual Report for 2023	18/04
Notice of annual general meeting in Cantargia AB (publ)	18/04
Cantargia publishes new data on the CAN10 antibody, detailing its interaction with IL1RAP and functional inhibition	17/04
Cantargia Publishes New Data on the Can10 Antibody, Detailing Its Interaction with IL1RAP and Functional Inhibition	17/04
Cantargia : Proposal regarding share-based incentive scheme	15/04
Cantargia : Proposal regarding guidelines for executive remuneration	15/04
Cantargia AB Publishes Preclinical Data on the Potential of CAN10 in Systemic Sclerosis in A Leading Scientific Journal	10/04
Cantargia publishes preclinical data on the potential of CAN10 in systemic sclerosis in a leading scientific journal	10/04
Cantargia AB Presents Unique Effects of Nadunolimab in Pancreatic Cancer	08/04
Cantargia presents unique effects of nadunolimab in pancreatic cancer	08/04
Cantargia Publishes Data Highlighting the Potential of CAN10 in Atherosclerosis	02/04
Cantargia publishes data highlighting the potential of CAN10 in atherosclerosis	02/04
Cantargia reports progress towards start of DOD-sponsored clinical trial of nadunolimab in leukemia	27/03
Cantargia AB Reports Progress Towards Start of DOT-Sponsored Clinical Trial of Nadunolimab in Leukemia	27/03
Cantargia Reports New Data Highlighting Potential of CAN10 Antibody, Currently in Phase I Clinical Development, as Therapy in Systemic Sclerosis	14/03
Cantargia presents new human data further supporting CAN10 in the treatment of systemic sclerosis	14/03
Cantargia Reports New Preclinical Data on Antitumor Effects of nadunolimab in Pancreatic Cancer	05/03
Cantargia reports new preclinical data on antitumor effects of nadunolimab in pancreatic cancer	05/03
Cantargia Q4 2023 - Progress with CAN10 and in PDA	23/02
Cantargia publishes Year-End Report for 2023	22/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Cantargia AB

Actions

CANTA

SE0006371126

Autres langues

Filtres